Verweij J - Search Results

1

Distribution of paclitaxel in plasma and cerebrospinal fluid.

Gelderblom H, Baker SD, Zhao M, Verweij J, Sparreboom A. Gelderblom H, et al. Among authors: verweij j. Anticancer Drugs. 2003 Jun;14(5):365-8. doi: 10.1097/00001813-200306000-00007. Anticancer Drugs. 2003. PMID: 12782943 Clinical Trial.

2

Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.

Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A. Gelderblom H, et al. Among authors: verweij j. J Clin Oncol. 2002 Jan 15;20(2):574-81. doi: 10.1200/JCO.2002.20.2.574. J Clin Oncol. 2002. PMID: 11786588 Clinical Trial.

3

Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.

Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A. Gelderblom H, et al. Among authors: verweij j. Clin Cancer Res. 2002 Apr;8(4):1237-41. Clin Cancer Res. 2002. PMID: 11948138 Clinical Trial.

4

Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry.

Sparreboom A, Zhao M, Brahmer JR, Verweij J, Baker SD. Sparreboom A, et al. Among authors: verweij j. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 25;773(2):183-90. doi: 10.1016/s1570-0232(02)00167-8. J Chromatogr B Analyt Technol Biomed Life Sci. 2002. PMID: 12031845

5

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.

Loos WJ, Szebeni J, ten Tije AJ, Verweij J, van Zomeren DM, Chung KN, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: verweij j. Anticancer Drugs. 2002 Aug;13(7):767-75. doi: 10.1097/00001813-200208000-00012. Anticancer Drugs. 2002. PMID: 12187334

6

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.

Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J. Smorenburg CH, et al. Among authors: verweij j. J Clin Oncol. 2003 Jan 15;21(2):197-202. doi: 10.1200/JCO.2003.01.058. J Clin Oncol. 2003. PMID: 12525510 Clinical Trial.

7

Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.

Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, Baker SD. Sparreboom A, et al. Among authors: verweij j. Clin Cancer Res. 2003 Jan;9(1):151-9. Clin Cancer Res. 2003. PMID: 12538463

8

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.

Loos WJ, Gelderblom H, Verweij J, van Boven-van Zomeren DM, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: verweij j. Anticancer Drugs. 2003 Mar;14(3):227-32. doi: 10.1097/00001813-200303000-00006. Anticancer Drugs. 2003. PMID: 12634617 Clinical Trial.

9

Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.

Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A. Loos WJ, et al. Among authors: verweij j. Clin Pharmacol Ther. 2003 Oct;74(4):364-71. doi: 10.1016/S0009-9236(03)00222-4. Clin Pharmacol Ther. 2003. PMID: 14534523

10

Effect of valspodar on the pharmacokinetics of unbound paclitaxel.

ten Tije AJ, Synold TW, Spicer D, Verweij J, Doroshow JH, Sparreboom A. ten Tije AJ, et al. Among authors: verweij j. Invest New Drugs. 2003 Aug;21(3):291-8. doi: 10.1023/a:1025412509730. Invest New Drugs. 2003. PMID: 14578679 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

927 results

Search Page

Filters